The Acting Chief Executive Officer of the proposed National Institute for Public Health and Infectious Diseases, Zaria, ...

Frisco Patients Seek Dentures Designed for a More Natural Appearance Frisco, United States - June 25, 2026 / Aesthetic ...

Anyone looking to upgrade their breakfast setup may be interested in Dunelm's "work of art" retro-style gloss toaster ...

Priority review for cemdisiran addresses adult anti-AChR–positive gMG, leveraging a priority review voucher and aligning US and EU regulatory timelines through 2027. RNAi-mediated C5 suppression ...

Legislation that complements President Trump’s executive order on name, image and likeness in college sports is advancing to ...

ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...

(Getty) Recent developments in complement biology and targeted therapies represent important advancements in addressing some of the unresolved challenges in AAV. Despite major therapeutic advances, ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

The FDA has approved Omeros' Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. It is the first FDA nod for the 31-year-old Seattle biotech.

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

Among the most significant genetic risk factors for age-related macular degeneration is the Y402H variant of complement factor H, which, along with its splice isoform FHL-1, impairs binding to the ...